Precision medicine diagnostics company Renalytix plc (LSE: RENX) (OTCQB: RNLXY) announced on Monday that it completed three additional clinical integrations of kidneyintelX.dkd in the United States during the final quarter of 2025, with initial testing volumes now underway at all sites. Integrations extend the company's electronic health record-connected, one-click ordering capability to support physician adoption of its FDA-approved and Medicare-reimbursed prognostic test for early-stage chronic kidney disease risk assessment.

Clinical deployments were completed at Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. Each is an established regional kidney care provider, with integrations implemented directly by Renalytix and embedded within existing clinical workflows. Utilisation is expected to scale as adoption broadens across patient populations.

Disciplined expansion of the clinical footprint remains a priority, with further healthcare provider integrations targeted for early calendar year 2026 to support scalable growth while maintaining efficient resource deployment.

Progress continues under the collaboration with Tempus AI, Inc, announced in September 2025, focused on advancing electronic health record integration and data collection across major US healthcare providers. Joint efforts are targeting providers with large diabetes and kidney disease populations, supporting longer-term development of data-driven kidney disease solutions and expansion into additional clinical and geographic markets.

Chief Executive Officer James McCullough is attending the J.P. Morgan Healthcare Conference in the United States this week as part of ongoing investor engagement, with a further corporate and trading update planned for February 2026.